Pfizer Inc is in discussions with 90 countries over supply contracts for its experimental COVID-19 pill, which was shown to reduce by 89% the risk of hospitalization or death in patients at high risk of severe illness, Chief Executive Officer Albert Bourla said in an interview on Friday.
Pfizer CEO Albert Bourla talks during a press conference with European Commission President Ursula von der Leyen after a visit to oversee the production of the Pfizer-BioNtech COVID-19 vaccine at the factory of U.S. pharmaceutical company Pfizer in Puurs, Belgium April 23, 2021.
Subscribe for our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
New COVID-19 pill cut hospital, death risk by 90%WASHINGTON (AP) — Pfizer Inc. said Friday that its experimental antiviral pill for COVID-19 cut rates of hospitalization and death by nearly 90% as the drugmaker joins the race to bring the first easy-to-use medication against the coronavirus to the U.S.
Lire la suite »
Pfizer says its experimental pill reduces risk of hospitalization, death from Covid-19Drugmaker Pfizer said Friday its experimental pill designed to fight coronavirus reduced the risk of hospitalization and death for high-risk patients taking part in a trial of the drug.
Lire la suite »
Pfizer says its antiviral pill slashes risk of severe COVID-19 by 89%(Reuters) -Pfizer Inc's experimental antiviral pill to treat COVID-19 was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday, offering what could be a promising new weapon in the fight against the pandemic. The trial's results suggest that the oral drug surpasses Merck & Co Inc's pill, molnupiravir, which was shown last month to halve the risk of dying or being hospitalized for COVID-19 patients at high risk of serious illness. Pfizer's pill, with the brand name Paxlovid, could secure U.S. regulatory approval by the end of the year.
Lire la suite »
Pfizer says its antiviral pill slashes risk of severe COVID-19 by 89%Pfizer Inc's experimental antiviral pill to treat COVID-19 was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday, offering what could be a promising new weapon in the fight against the pandemic.
Lire la suite »
Pfizer Says Its COVID-19 Pill Is Highly EffectiveAn experimental antiviral pill appears to work very well at keeping people who are at high risk of severe COVID-19 from being admitted to the hospital and dying, according to the drug’s maker, Pfizer.
Lire la suite »